Cibinetide (ARA-290)
Cibinetide (ARA-290) • Also called ARA-290, ARA 290
Cibinetide, also called ARA-290, appears in neuropathy and tissue-repair discussions but does not currently have a dependable compounding position.
Current status
Restricted
Nerve-related and recovery interest, with current federal compounding constraints still in play.
FDA category
Category 3
Can pharmacies compound this?
No
Reclassification expected?
Unclear
The main current signal is that FDA did not receive enough support to keep the nomination under active evaluation.
Primary Use
Nerve-related and recovery interest
Also searched as
ARA-290, ARA 290
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Sep 27, 2024
Current status signal recorded: Placed by FDA in Category 3 because the nomination lacked adequate support..
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when Cibinetide (ARA-290) status changes
State-specific notes
California
Specialty peptides without a strong federal footing face especially cautious sourcing.